Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation

Background/Aims De novo autoimmune hepatitis (AIH) describes the development of hepatitis with autoimmune features in liver transplant (LT) patients without prior diagnosis of AIH. We aimed to evaluate the incidence and risk factors for de novo AIH. Methods A cohort of 576 patients with LT for aetiologies other than AIH was evaluated. Results De novo AIH was diagnosed in 17 patients (3%) with an overall incidence of 4.0 cases per 1000 patient-years. By univariate Cox analysis, patients who received cyclosporine A had lower risk (HR 0.24, 95% CI 0.070.80, P similar to=similar to 0.02), whereas patients who had female donors (HR 3.03, 95% CI 1.118.25, P similar to=similar to 0.03), donors =40-years (HR 6.95, 95% CI 1.9325.03, P similar to=similar to 0.003), and those who received tacrolimus (HR 4.39, 95% CI 1.4713.13, P similar to=similar to 0.008) and mycophenolate mofetil (HR 6.37, 95% CI 1.6225.13, P similar to=similar to 0.008) had higher risk. Survival was similar in patients with de novo AIH compared with the LT population (mean survival time, 17 similar to+/-similar to 1.5 vs. 16 similar to+/-similar to 0.5 similar to years, Log-rank test; P similar to=similar to 0.4). Conclusions The incidence of de novo AIH is low and does not impact on long-term survival. Recipients of female or older donor grafts, or recipients using tacrolimus, or mycophenolate mofetil as part of their immunosuppressive regimen have a higher risk of de novo AIH, whereas LT recipients maintained on cyclosporine A have a lower risk.